Eribulin and Lenvatinib in Advanced Solid Tumors

Cancer Clinical Trial

Official title:

Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02640508
• Other study ID #: CTMS 15-2139
• Secondary ID: HSC20150891H
• Status: Completed
• Phase: Phase 2
• Start date: May 2016
• Est. completion date: January 12, 2023

Study information

• Verified date: April 2024
• Source: The University of Texas Health Science Center at San Antonio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.

Description:

This is a phase II clinical trial of the combination of eribulin, and Lenvatinib. A cycle will be defined as 21 days. Eribulin will be given on days 1 and 8 of each cycle. Lenvatinib will be given daily during each cycle.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: January 12, 2023
• Est. primary completion date: November 24, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Stage IV breast cancer, stage IV NSCLC (Non-Small Cell Lung Cancer) (, stage IV sarcoma

• ECOG (Eastern Cooperative Oncology Group) PS (Performance Status) 0-2

• Measurable disease

• No more than 4 prior chemotherapeutic regimens for metastatic disease

• Patients must be >/= 18 years.

• Patients may not have received eribulin or lenvatinib previously

• Patients must have a life expectancy of greater than 12 weeks.

• Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment and are considered free of disease.

• Patients must have normal organ and marrow function as defined below:

Leukocytes = 3,000/uL Absolute neutrophil count = 1,500/uL Platelets = 100,000/uL Child Pugh score = 10 Patients must be able to swallow and retain oral medication. All patients must have given signed, informed consent prior to registration on study.

Exclusion Criteria:

• Women who are pregnant or lactating are not eligible for study treatment.

• Patients who are undergoing concomitant radiotherapy are NOT eligible for participation.

• Patients who are receiving any other investigational agents or concurrent anticancer therapy are NOT eligible for participation. Previous systemic treatment and/or radiation therapy is allowed with a 14 day washout period prior to registration.

• Lesions that have been radiated previously cannot be considered target lesions

• Prior treatment related side effects must have resolved to < Grade 2 severity per Common Terminology Criteria for Adverse Events (CTCAE version 4.03), except alopecia and infertility.

• Patients who are taking any herbal (alternative) medicines are NOT eligible for participation. Patients must be off any such medications by the time of registration.

• Patients with known brain metastases are NOT eligible for participation unless the brain metastases are treated (either with surgical excision, stereotactic radiosurgery or radiotherapy) and have been stable for at least 4 wks per MR performed, the patient is asymptomatic and has discontinued corticosteroids if taken for that purpose.

• Patients with any of the following conditions or complications are NOT eligible for participation:

1. GI tract disease resulting in an inability to take oral medication

2. Malabsorption syndrome

3. Require IV alimentation

4. History of prior surgical procedures affecting absorption

5. Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).

6. Hypersensitivity of any of the components of eribulin or lenvatinib

7. History of significant neurological ( no neuropathy more than grade 2) or psychiatric disorders

8. Significant non neoplastic liver disease (Cirrhosis, active chronic hepatitis)

9. Immunocompromised subjects, including patients with human immunodeficiency virus

10. Significant non neoplastic renal disease

11. Active infection requiring systemic therapy.

12. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment

13. Prolongation of QTc interval to more than 480 milliseconds when electrolyte balance is normal

14. Major surgery within 4 weeks prior to first dose of the study drug.

Related Conditions & MeSH terms

• Cancer
• Neoplasms
• Solid Tumor

Intervention

Drug:
• Eribulin
Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
• Lenvatinib
Will be taken orally at 20-24 mg daily in each 21 day cycle.

Locations

Country	Name	City	State
United States	Cancer Therapy and Research Center University of Texas Health Science Center San Antonio	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Virginia G. Kaklamani	Eisai Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate of Lenvatinib and Eribulin (Phase II)	Defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) as assessed by independent imaging review.	The overall response rate will be assessed after two cycles of therapy (1 cycle = 3 weeks) until the date of first documentation of disease progression or death (whichever occurs first) over an average of 18 months.
Primary	Progression Free Survival	Progression-free survival (PFS) will be defined as the time from the first study treatment to the first occurrence of progression or death.	Baseline to 50 months
Secondary	Overall Survival Rate		Baseline to 50 months
Secondary	Lenvatinib and Eribulin Toxicities Will be Graded Using NCI CTCAE Version 4.03	Adverse events are graded in the NCI CTCAE version 4.03 scale and reported by number of adverse events per grade	Safety will be evaluated from the time of registration until 30 days after last dose of treatment, resolution of the related AE or death up to 40 months.